Patents by Inventor Rainer Kleeman

Rainer Kleeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE
    Publication number: 20130203690
    Abstract: Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 8, 2013
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleeman, Christian Troetschel, Andrea Vollmar
  • Use of PDE III Inhibitors for the Treatment of Asymptomatic (Occult) Heart Failure
    Publication number: 20100273807
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patents having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having an asymptomatic (occult) heart failure of a patient suffering from asymptomatic heart disease.
    Type: Application
    Filed: July 7, 2010
    Publication date: October 28, 2010
    Inventors: Rainer Kleeman, Christian Troetschel, Andrea Vollmar
  • USE OF PDE III INHIBITORS FOR THE TREAMENT OF ASYMPTOMATIC (OCCULT) HEART FAILURE
    Publication number: 20070112010
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having an asymptomatic (occult) heart failure of a patient suffering from asymptomatic heart disease.
    Type: Application
    Filed: November 14, 2006
    Publication date: May 17, 2007
    Inventors: Rainer Kleeman, Christian Troetschel, Andrea Vollmar
  • Pharmaceutical composition for the treatment of disorders of non-human mammals
    Publication number: 20030162796
    Abstract: Pharmaceutical composition for the treatment of disorders, in particular for the treatment of mammary tumors of a non-human mammal, which is associated with an aberrant activity of one or more tyrosine kinase receptors. The composition contains, as the active ingredient, one or more substances that inhibit the aberrant activity of the tyrosine kinase receptor(s) of said animal, in particular the Epidermal Growth Factor Receptor (EGFR) and/or HER2. The pharmaceutical composition is particularly useful for the treatment of dogs.
    Type: Application
    Filed: September 30, 2002
    Publication date: August 28, 2003
    Inventors: Frank Hilberg, Iris Brandstetter, Peter Bette, Rainer Kleeman, Jacobus van Meel